Skip to search formSkip to main contentSkip to account menu

Namilumab

Known as: Immunoglobulin G1, Anti-(Human Colony-Stimulating Factor 2) (Human Monoclonal MT203 Heavy Chain), Disulfide With Human Monoclonal MT203 Kappa-Chain, Dimer, MT203 
A human IgG1, monoclonal antibody targeting GM-CSF, with immunomodulating activity. Namilumab binds to and neutralizes GM-CSF, by preventing GM-CSF… 
National Institutes of Health

Related topics

Related topics

2 relations
Granulocyte-Macrophage Colony-Stimulating Factorantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
COVID vaccine results pour in
the drug as a frontrunner among the anti-GM-CSF mAbs under development. Mavrilimumab eliminated deaths in the treated group, with… 
2019
2019
Namilumab improves RA symptoms
2019
2019
Faculty Opinions recommendation of Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid…
  • L. Šenolt
  • Faculty Opinions – Post-Publication Peer Review…
  • 2019
  • Corpus ID: 201959471
2018
2018
Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men
.
OBJECTIVE Namilumab is an investigational human monoclonal antibody to human granulocyte-macrophage colony-stimulating factor (GM… 
2015
2015
SAT0210 First-in-Patient Study of Namilumab, an Anti-GM-CSF Monoclonal Antibody, in Active Rheumatoid Arthritis: Results of the Priora Phase IB Study
Background Granulocyte macrophage-colony stimulating factor (GM-CSF) plays an important role in inflammation. Namilumab (AMG 203… 
2015
2015
AB0484 An Integrated Pharmacokinetic and Pharmacodynamic Approach to Guide Dose Selection of Namilumab, an Anti-GM-CSF Monoclonal Antibody, for Phase II Rheumatoid Arthritis Studies
Background Granulocyte macrophage-colony stimulating factor (GM-CSF) is a soluble cytokine known to play a role in various… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)